Role of poly(adenosine diphosphate-ribose) polymerase 1 in septic peritonitis

Current Opinion in Critical Care

Volumn 9, Issue 2, 2003, Pages 152-158

  Liaudet, Lucas ^a   Oddo, Mauro ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; FREE RADICAL; GLUCOSYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OXIDIZING AGENT; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

BACTERIAL PERITONITIS; CELL DEATH; CRITICAL ILLNESS; CYTOPATHOLOGY; ENZYME ACTIVATION; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; INFLAMMATORY DISEASE; MITOCHONDRIAL RESPIRATION; MULTIPLE ORGAN FAILURE; MYOCARDIAL DISEASE; NONHUMAN; PROTEIN FUNCTION; REVIEW; SEPTIC SHOCK; SIGNAL TRANSDUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DNA DAMAGE; ENZYME ACTIVATION; HUMANS; MULTIPLE ORGAN FAILURE; PERITONITIS; POLY(ADP-RIBOSE) POLYMERASES; SEPSIS;

EID: 0037386212     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200304000-00012     Document Type: Review

References (48)

1. Liaudet L: Poly(ADP-ribose) polymerase as a cause of metabolic dysfunction in critical illness. Curr Opin Clin Nutr Metab Care 2002, 5:175-184. This complete review focuses on the roles of PARP-1 activation in the development of cytopathic hypoxia in pathologies encountered in critical care patients.
2. Shall S, de Murcia G: Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat Res 2000, 460:1-15.
3. Virag L, Szabo C: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev 2002, 54:375-429. An outstanding article that fully revises all the aspects of PARP-1 biology and critically appreciates the current state of knowledge of the pathologic roles of PARP-1 in inflammation, circulatory shock, diabetes, and cancer. This review also summarizes recent developments in the pharmacology of PARP-1 inhibitors.
4. Davidovic L, Vodenicharov M, Affar EB, et al.: Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp Cell Res 2001, 268:7-13.
5. Herceg Z, Wang Z: Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. Mutat Res 2001, 477:97-110.
6. Ha HC, Snyder SH: Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci U S A 1999, 96:13978-13982.
7. Liaudet L, Soriano FG, Szabó C: Poly(ADP-ribose) synthetase as a novel therapeutic target for circulatory shook. In Yearbook of Intensive Care and Emergency Medicine. Edited by Vincent JL. Heidelberg: Springer-Verlag; 2001:78-89.
8. Liaudet L, Garcia-Soriano F, Szabo C: Biology of nitric oxide signaling. Crit Care Med 2000, 28(suppl 4):N37-N52.
9. Liaudet L, Szabó E, Timashpolsky L, et al.: Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences. Br J Pharmacol 2001, 133:1424-1430.
10. Kooy NW, Royall JA, Ye YZ, et al.: Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med 1995, 151:1250-1254.
11. Liaudet L, Soriano FG, Szabo E, et al.: Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc Natl Acad Sci U S A 2000, 97:10203-10208.
12. Szabo C, Salzman AL, Ischiropoulos H: Endotoxin triggers the expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in the rat aorta in vivo. FEBS Lett 1995, 363:235-238.
13. Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
14. Parker SJ, Watkins PE: Experimental models of gram-negative sepsis. Br J Surg 2001, 88:22-30.
15. + content, responsible for a reduction in oxygen consumption by the cells.
16. Cuzzocrea S, Zingarelli B, Caputi AP: Peroxynitrite-mediated DNA strand breakage activates poly(ADP-ribose) synthetase and causes cellular energy depletion in a nonseptic shock model induced by zymosan in the rat. Shock 1998, 9:336-340.
17. Pulido EJ, Shames BD, Selzman CH, et al.: Inhibition of PARS attenuates endotoxin-induced dysfunction of pulmonary vasorelaxation. Am J Physiol 1999, 277:L769-L776.
18. Szabo C, Zingarelli B, Salzman AL: Role of poly-ADP ribosyltransferase activation in the vascular contractile and energetic failure elicited by exogenous and endogenous nitric oxide and peroxynitrite. Circ Res 1996, 78:1051-1063.
19. Zingarelli B, O'Connor M, Wong H, et al.: Peroxynitrite-mediated DNA strand breakage activates poly-ADP-ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol 1996, 156:350-358.
20. Chabot F, Mitchell JA, Quinlan GJ, et al.: Characterization of the vasodilator properties of peroxynitrite on rat pulmonary artery: role of poly(adenosine 5′-diphosphoribose) synthase. Br J Pharmacol 1997, 121:485-490.
21. Cuzzocrea S, Zingarelli B, Caputi AP: Role of peroxynitrite and poly (ADP-ribosyl) synthetase activation in cardiovascular derangement induced by zymosan in the rat. Life Sci 1998, 63:923-933.
22. Jagtap P, Garcia Soriano F, Virag L, et al.: Novel phenanthridinone inhibitors of poly(adenosine-5′-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med 2002, 30:1071-1082. This article describes the activity of a new class of PARP-1 inhibitors (phenanthridinone compounds) in selected in vitro systems and in reperfusion injury and circulatory shock in vivo.
23. Zingarelli B, Salzman AI, Szabo C: Protective effects of nicotinamide against nitric oxide-mediated delayed vascular failure in endotoxic shock: potential involvement of polyADP-ribosyl synthetase. Shock 1996, 5:258-264.
24. Garcia Soriano F, Virag L, Jagtap P, et al.: Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001, 7:108-113.
25. Villa LM, Salas E, Darley-Usmar VM, et al.: Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci U S A 1994, 91:12383-12387.
26. Szabo C, Cuzzocrea S, Zingarelli B, et al.: Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite. J Clin Invest 1997, 100:723-735.
27. Pacher P, Cziráki A, Mabley JG, et al.: Role of poly(ADP-ribose) polymerase activation in the endotoxin-induced cardiac collapse in rodents. Biochem Pharmacol 2002, 64:1785-1791. The authors show that the impairment of left systolic and diastolic ventricular function induced by endotoxin in rodents is dependent on the activation of PARP-1.
28. Docherty JC, Kuzio B, Silvester JA, et al.: An inhibitor of poly (ADP-ribose) synthetase activity reduces contractile dysfunction and preserves high energy phosphate levels during reperfusion of the ischaemic rat heart. Br J Pharmacol 1999, 127:1518-1524.
29. Szabo G, Bahrle S, Stumpf N, et al.: Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res 2002, 90:100-106.
30. Cuzzocrea S, Zingarelli B, Costantino G, et al.: Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat. Crit Care Med 1999, 27:1517-1523.
31. Szabo C, Lim LH, Cuzzocrea S, et al.: Inhibition of poly (ADP-ribose) synthetase attenuates neutrophil recruitment and exerts antiinflammatory effects. J Exp Med 1997, 186:1041-1049.
32. Wray GM, Hinds CJ, Thiemermann C: Effects of inhibitors of poly(ADP-ribose) synthetase activity on hypotension and multiple organ dysfunction caused by endotoxin. Shock 1998, 10:13-19.
33. Kuhnle S, Nicotera P, Wendel A, et al.: Prevention of endotoxin-induced lethality, but not liver apoptosis in poly(ADP-ribose) polymerase-deficient mice. Biochem Biophys Res Commun 1999, 263:433-438.
34. Szabo A, Salzman AL, Szabo C: Poly (ADP-ribose) synthetase activation mediates pulmonary microvascular and intestinal mucosal dysfunction in endotoxin shock. Life Sci 1998, 63:2133-2139.
35. Taner AS, Cinel I, Ozer L, et al.: Poly(adp-ribose) synthetase inhibition reduces bacterial translocation in rats after endotoxin challenge. Shock 2001, 16:159-162. This is a well-designed study investigating the role of PARP-1 in mucosal barrier dysfunction of the small intestine in rat endotoxic shock. It is shown that the PARP-1 inhibitor 3-aminobenzamide reduces the damage elicited in the gut by endotoxin, thereby preventing the development of bacterial translocation to mesenteric lymph nodes.
36. Liaudet L, Szabo A, Garcia-Soriano F, et al.: Poly(ADP-ribose) synthetase mediates intestinal dysfunction after mesenteric ischemia. Shock 2000, 14:134-141.
37. Deitch EA: Role of the gut lymphatic system in multiple organ failure. Curr Opin Crit Care 2001, 7:92-98.
38. Goldfarb RD, Marton A, Szabo E, et al.: Protective effect of a novel, potent inhibitor of poly(adenosine-5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med 2002, 30:974-980. This article defines a critical role of PARP-1 in the development of myocardial dysfunction in a clinically relevant model of septic peritonitis, induced by the intraperitoneal implantation of E. coli-laden fibrin clots in the pig.
39. Soriano FG, Liaudet L, Szabo E, et al.: Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1- deficient mice. Shock 2002, 17:286-292. In this study, the response to septic peritonitis induced by cecal ligation and puncture is compared in PARP-1 wild-type and PARP-1 deficient mice. The main results indicate that PARP-1 genetic suppression reduces tissue injury, limits the increase in plasma cytokines, and significantly improves survival.
40. Baechtold F, Scott JA, Markert M, et al.: Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock 2001, 16:137-142.
41. Szabo C: Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture? Shock 2002, 17:439-440.
42. Le Page C, Pellat-Deceunynck C, Drapier JC, et al.: Effects of inhibitors of ADP-ribosylation on macrophage activation. Adv Exp Med Biol 1997, 419:203-207.
43. Oliver FJ, Menissier-de Murcia J, Nacci C, et al.: Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. EMBO J 1999, 18:4446-4454. This article provides the first demonstration of a close functional association between PARP-1 and the transcription factor nuclear factor κB.
44. Szabo C, Virag L, Cuzzocrea S, et al.: Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthetase. Proc Natl Acad Sci U S A 1998, 95:3867-3872.
45. Fukuzawa M, Satoh J, Muto G, et al.: Inhibitory effect of nicotinamide on in vitro and in vivo production of tumor necrosis factor-alpha. Immunol Lett 1997, 59:7-11.
46. Zingarelli B, Salzman AL, Szabo C: Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ Res 1998, 83:85-94.
47. Senftleben U, Karin M: The IKK/NF-kappaB pathway. Crit Care Med 2002, 30:S18-S26.
48. Ha HC, Hester LD, Snyder SH: Poly(ADP-ribose) polymerase-1 dependence of stress-induced transcription factors and associated gene expression in glia. Proc Natl Acad Sci U S A 2002, 99:3270-3275. The authors show that PARP-1 modulates the activation of a broad range of transcription factors in vitro, thereby regulating the expression of various inflammatory mediators.